January 8, 2021 Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study https://t.co/SWYQL8prqx
We are excited to announce today that Leading BioSciences has entered into an agreement to merge with Seneca Biopharma to create Palisade Bio, a publicly-traded NASDAQ listed company focused on advancing much needed treatments protecting the GI system. https://prn.to/ 2LOVDJX #$SNCA #$PALI
Finally! GI symptoms officially recognized as part of COVID-19. https://t.co/4R1dyV3EGM
Early Release! Excellent analysis of new data showing evidence of live #SARSCoV2 virus in feces of patient with sev… https://t.co/UA1vSWGd3F
Wonderfully written piece by Jonathan Wosen @JonathanWosen at San Diego Union-Tribune @sdut on the FDA's clearance… https://t.co/P9RoLWhLoQ
Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 Study
Proteases promote SARS-CoV-2 infection of human small intestinal enterocytes! https://t.co/razZg6hfZh
Study found bowel abnormalities on imaging in patients with COVID-19, more commonly in sicker patients who went to… https://t.co/I5CrUjoM1o
Digestive issues were the first symptom of coronavirus for 5 children admitted to the emergency department. None of… https://t.co/lLcvkLxeR1
Leading BioSciences is offering our investigational drug, LB1148 as a potential therapy for COVID-19 patients. Please read our white paper on the connections between #COVID19 and GI tract symptoms/ dysfunctionhttps:// www.yumpu.com/ en/document/ read/63163485/ lb1148-for-the-t reatment-of-cov id-19-march-21- 2020
Similar Businesses
